[go: up one dir, main page]

WO2024263130A1 - A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor - Google Patents

A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor Download PDF

Info

Publication number
WO2024263130A1
WO2024263130A1 PCT/TR2024/050639 TR2024050639W WO2024263130A1 WO 2024263130 A1 WO2024263130 A1 WO 2024263130A1 TR 2024050639 W TR2024050639 W TR 2024050639W WO 2024263130 A1 WO2024263130 A1 WO 2024263130A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
formulation according
sodium
mixtures
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/TR2024/050639
Other languages
French (fr)
Inventor
Onur Mutlu
Busra ARI
Fatih Sunel
Fadime Bilgehan ATAK
Seval Ataman
Ozlem YAZICI
Onder SARP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2023/007200 external-priority patent/TR2023007200A1/en
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2024263130A1 publication Critical patent/WO2024263130A1/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a pharmaceutical formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • linagliptin 8-[(3R)-3-aminopiperidin-l-yl]-7-but-2-yn-l-yl)-3-methyl-l-[(4- methylquinazolin-2-yl)methyl]-3,7-dihydro-lH-purine-2, 6-dione and its chemical structure is shown in the Formula I.
  • Metformin is antidiabetics having an orally-administrated biguanide structure.
  • Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
  • metformin hydrochloride is 1,1-dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
  • a combination therapy of linagliptin with metformin HCI provides an even more effective treatment of type II diabetes.
  • Linagliptin in combination with Metformin is marketed in the United States under the brand name Jentadueto’ by Boehringer Ingelheim.
  • the SGLT2 inhibitor is a class of medications that modulate sodium-glucose transport proteins in the nephron and is used in the treatment of type II diabetes mellitus. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefits in patients with type II diabetes.
  • SGLT2 inhibitor is administered at a dose from about 0.5 to about 200 mg/day, and insulin or other oral anti-diabetic agents are also administered at a dose as prescribed by a doctor.
  • the main object of the present invention is to obtain a stable combination comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor with synergistic effect for use in treatment of a type 2 diabetes in a mammalian or/and heart disease.
  • Another object of the present invention is to provide a formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.
  • Another object of the present invention is to provide a formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor having the desired dissolution profile, homogeneity, high stability, and flowability.
  • the pharmaceutical formulation comprises;
  • Linagliptin or salts thereof, metformin or salts thereof, A SGLT-2 inhibitor Linagliptin or salts thereof, metformin or salts thereof, A SGLT-2 inhibitor.
  • metformin hydrochloride and linagliptin are used.
  • SGLT2 inhibitor is selected from the group comprising canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, tofogliflozin.
  • the SGLT2 inhibitor is dapagliflozin.
  • the SGLT2 inhibitor is empagliflozin.
  • the SGLT2 inhibitor is canagliflozin.
  • the SGLT2 inhibitor is ertugliflozin. According to one embodiment of the present invention, the SGLT2 inhibitor is ipragliflozin.
  • the SGLT2 inhibitor is tofogliflozin.
  • the SGLT2 inhibitor is luseogliflozin.
  • the SGLT2 inhibitor is remogliflozin etabonate.
  • the amount of linagliptin or salts thereof is between 0.1% and 3.0% by weight in the total formulation.
  • the amount of metformin or salts thereof is between 60.0% and 80.0% by weight in the total formulation.
  • the amount of a SGLT2 inhibitor is between 0.1% and 15.0% by weight in the total formulation.
  • the pharmaceutical formulation comprises linagliptin is present in an amount of 5mg.
  • the pharmaceutical formulation comprises metformin is present in an amount of between 500 mg and 1000 mg.
  • the pharmaceutical formulation comprises a SGLT2 inhibitor is present in an amount of between 5 mg and 300 mg.
  • This combination can be also used to reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes.
  • excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of active agents. For this reason, the excipients which accompany active agents have to be selected in a careful and conscious manner while a formulation is developed.
  • the formulations should have no physicochemical incompatibility between the active agents and the excipients.
  • the formulation further comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
  • Suitable fillers are selected from the group comprising ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose acetate, compressible sugar, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, lactose, mannitol, lactose monohydrate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, microcrystalline cellulose, polydextrose, polymethacrylates, sodium alginate, sodium chloride, starch, sucrose, sugar spheres, talc, polysorbate 80, xylitol or mixtures thereof.
  • the filler is microcrystalline cellulose or lactose or lactose monohydrate or mannitol or mixtures thereof.
  • the amount of the filler is between 10.0% and 40.0 by weight in the total formulation.
  • the amount of the filler provides the desired flowability.
  • the advantages of the present invention are even more significant, as the problem of homogeneity is even more likely to occur when three active substances are incorporated in one final dosage form, especially when active substances are used very different regarding the amount. Improved content uniformity efficiently contributes to a marked increase in bioavailability.
  • used binder provides the desired content uniformity.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, carboxymethylcellulose calcium, cellulose acetate phthalate, starch, corn starch, pregelatinized starch, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropyl methyl cellulose, polyoxyethilene-alkyl ethers or mixtures thereof.
  • the binder is carboxymethylcellulose sodium or polyvinylpyrrolidone or corn starch or HPMC or mixtures thereof. Also, the binders help to provide the desired stability.
  • the amount of the binder is between 0.5% and 10.0 by weight in the total formulation.
  • Suitable disintegrants are selected from the group comprising crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, sodium alginate, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
  • the disintegrant is crospovidone or croscarmellose sodium or mixtures thereof.
  • the amount of disintegrant is between 1.0% and 15.0% by weight in the total formulation.
  • the ratio helps to provide the desired dissolution profile and stability.
  • Suitable lubricants are selected from the group comprising magnesium stearate, talc, calcium stearate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • the lubricant is magnesium stearate or sodium stearyl fumarate or talc or mixtures thereof.
  • Suitable glidants are selected from the group comprising aluminum silicate, colloidal silicon dioxide, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
  • the glidant is colloidal silicon dioxide.
  • the pharmaceutical formulation is in the form of tablets, capsules, orally disintegrating tablets, effervescent compositions, hard or soft gelatin capsules, coated bead systems, granules, microspheres.
  • the pharmaceutical formulation is in the form of tablet or capsule.
  • tablets are selected from the group comprising film-coated tablets, bilayer tablets, inlay tablets, orally disintegrating tablets, multilayer tablets, mini tablets, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, gastric disintegrating tablets.
  • the pharmaceutical formulation is formulated as film coated tablet or bilayer tablet or multilayer tablet or modified release tablet.
  • the pharmaceutical formulation is formulated in capsule form which is selected from the group comprising hard capsule, soft capsule, and enteric capsule.
  • the capsule comprises at least one type of particle, for example; mini-capsules, mini-tablets, pellets, cores, agglomerates, granules, powders, liposomes, spherical or mixtures thereof.
  • the pharmaceutical formulation of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • the formulation is prepared, using wet or dry granulation.
  • Solvent is used in wet granulation. Suitable solvents are selected from the group comprising dichloromethane, 0.1N HCI, water, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether, propylene carbonate or mixtures thereof. Preferably, solvent is water or ethanol or mixtures thereof.
  • a wet granulation process for preparing a pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) Mixing linagliptin, metformin and canagliflozin or empagliflozin or dapagliflozin with croscarmellose sodium, microcrystalline cellulose, b) Granulating the mixture with aqueous solution of HPMC, c) Drying the granules and sieving, d) Mixing with mg-stearate, e) Compressing into tablet , f) Performing a film coating with PVA base solution,
  • a direct compression process for preparing a pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) Mixing linagliptin, metformin DC grade and canagliflozin or empagliflozin or dapagliflozin with croscarmellose sodium, microcrystalline cellulose, b) Adding mg-stearate and sodium stearyl fumarate and mix, c) Compressing into tablets, d) Performing a film coating with PVA base solution.
  • a wet granulation process for preparing a bilayer pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) As first layer; Granulating metformin with an aqueous solution of Karboksimetilsommeoz sodyum (7 HF) and HPMC b) Drying the granules and mixing with mg-stearate, c) As second layer; linagliptin, dapagliflozin, mannitol DC; pregelatinized starch, corn starch, copovidone and crospovidone is mixed. Mixture is lubricated with mg-stearate and talc, d) Optionally, linagliptin could be prepared in film coating solution and coated onto tablets.
  • Example 2 A tablet
  • Example 3 A tablet
  • Example 4 A tablet
  • Example 5 A tablet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.

Description

A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2
INHIBITOR
Field of the Invention
The present invention relates to a pharmaceutical formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.
Background of the Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin. There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
The chemical name of linagliptin is 8-[(3R)-3-aminopiperidin-l-yl]-7-but-2-yn-l-yl)-3-methyl-l-[(4- methylquinazolin-2-yl)methyl]-3,7-dihydro-lH-purine-2, 6-dione and its chemical structure is shown in the Formula I.
Figure imgf000002_0001
Formula I Metformin is antidiabetics having an orally-administrated biguanide structure. Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform. Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
The chemical name of metformin hydrochloride is 1,1-dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
Figure imgf000003_0001
Formula II
A combination therapy of linagliptin with metformin HCI provides an even more effective treatment of type II diabetes. Linagliptin in combination with Metformin is marketed in the United States under the brand name Jentadueto’ by Boehringer Ingelheim.
It is known for treating a type 2 diabetes in a mammalian patient who has previously been treated with one or more oral anti-diabetic agents and/or one or more injectable anti-diabetic agents (e.g., insulin). Sometimes these are considered insufficient.
Limited improvement in glycemic control is observed with long-term treatment. In addition, even in patients within the intensive treatment glycemic control can deteriorated significantly over time by deterioration of -cell function.
The SGLT2 inhibitor is a class of medications that modulate sodium-glucose transport proteins in the nephron and is used in the treatment of type II diabetes mellitus. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefits in patients with type II diabetes. SGLT2 inhibitor is administered at a dose from about 0.5 to about 200 mg/day, and insulin or other oral anti-diabetic agents are also administered at a dose as prescribed by a doctor.
Therefore, there is thus still a need for methods, medicaments and pharmaceutical combinations with a good efficacy with regard to glycemic control, with regard to disease-modifying properties and with regard to reduction of cardiovascular morbidity and mortality while at the same time showing an improved safety profile. In this invention, combining more than two molecules in one dosage form increases the patient's compliance. The combination brings additional advantages to the relevant prior art. The term "combination" means that when drugs are administered together, a combined action is obtained which is higher than the individual actions of the respective drugs when they are used separately. On the other hand, using a lower dose of each drug to be combined according to the present invention will reduce the total dosage. These are advantageous in terms of patients to be treated.
Detailed Description of the Invention
The main object of the present invention is to obtain a stable combination comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor with synergistic effect for use in treatment of a type 2 diabetes in a mammalian or/and heart disease.
Another object of the present invention is to provide a formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.
Another object of the present invention is to provide a formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor having the desired dissolution profile, homogeneity, high stability, and flowability.
According to one embodiment of the present invention, the pharmaceutical formulation comprises;
Linagliptin or salts thereof, metformin or salts thereof, A SGLT-2 inhibitor.
According to one embodiment of the present invention, metformin hydrochloride and linagliptin are used.
SGLT2 inhibitor is selected from the group comprising canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, tofogliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is dapagliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is empagliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is canagliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is ertugliflozin. According to one embodiment of the present invention, the SGLT2 inhibitor is ipragliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is tofogliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is luseogliflozin.
According to one embodiment of the present invention, the SGLT2 inhibitor is remogliflozin etabonate.
According to one embodiment of the present invention, the amount of linagliptin or salts thereof is between 0.1% and 3.0% by weight in the total formulation.
According to one embodiment of the present invention, the amount of metformin or salts thereof is between 60.0% and 80.0% by weight in the total formulation.
According to one embodiment of the present invention, the amount of a SGLT2 inhibitor is between 0.1% and 15.0% by weight in the total formulation.
According to one embodiment of the present invention, the pharmaceutical formulation comprises linagliptin is present in an amount of 5mg.
According to one embodiment of the present invention, the pharmaceutical formulation comprises metformin is present in an amount of between 500 mg and 1000 mg.
According to one embodiment of the present invention, the pharmaceutical formulation comprises a SGLT2 inhibitor is present in an amount of between 5 mg and 300 mg.
This combination can be also used to reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes.
In general terms, excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of active agents. For this reason, the excipients which accompany active agents have to be selected in a careful and conscious manner while a formulation is developed. The formulations should have no physicochemical incompatibility between the active agents and the excipients. According to this embodiment of the present invention, the formulation further comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
Suitable fillers are selected from the group comprising ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose acetate, compressible sugar, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, lactose, mannitol, lactose monohydrate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, microcrystalline cellulose, polydextrose, polymethacrylates, sodium alginate, sodium chloride, starch, sucrose, sugar spheres, talc, polysorbate 80, xylitol or mixtures thereof.
According to one embodiment of the present invention, the filler is microcrystalline cellulose or lactose or lactose monohydrate or mannitol or mixtures thereof.
According to one embodiment of the present invention, the amount of the filler is between 10.0% and 40.0 by weight in the total formulation. The amount of the filler provides the desired flowability.
The advantages of the present invention are even more significant, as the problem of homogeneity is even more likely to occur when three active substances are incorporated in one final dosage form, especially when active substances are used very different regarding the amount. Improved content uniformity efficiently contributes to a marked increase in bioavailability. In this invention, used binder provides the desired content uniformity.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, carboxymethylcellulose calcium, cellulose acetate phthalate, starch, corn starch, pregelatinized starch, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropyl methyl cellulose, polyoxyethilene-alkyl ethers or mixtures thereof.
According to one embodiment of the present invention, the binder is carboxymethylcellulose sodium or polyvinylpyrrolidone or corn starch or HPMC or mixtures thereof. Also, the binders help to provide the desired stability.
According to one embodiment of the present invention, the amount of the binder is between 0.5% and 10.0 by weight in the total formulation. Suitable disintegrants are selected from the group comprising crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, sodium alginate, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
According to one embodiment of the present invention, the disintegrant is crospovidone or croscarmellose sodium or mixtures thereof.
According to one embodiment of the present invention, the amount of disintegrant is between 1.0% and 15.0% by weight in the total formulation. The ratio helps to provide the desired dissolution profile and stability.
Suitable lubricants are selected from the group comprising magnesium stearate, talc, calcium stearate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
According to one embodiment of the present invention, the lubricant is magnesium stearate or sodium stearyl fumarate or talc or mixtures thereof.
Suitable glidants are selected from the group comprising aluminum silicate, colloidal silicon dioxide, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
According to one embodiment of the present invention, the glidant is colloidal silicon dioxide.
According to one embodiment of the present invention, the pharmaceutical formulation is in the form of tablets, capsules, orally disintegrating tablets, effervescent compositions, hard or soft gelatin capsules, coated bead systems, granules, microspheres.
According to one embodiment of the present invention, the pharmaceutical formulation is in the form of tablet or capsule.
According to one embodiment of the present invention, tablets are selected from the group comprising film-coated tablets, bilayer tablets, inlay tablets, orally disintegrating tablets, multilayer tablets, mini tablets, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, gastric disintegrating tablets.
According to one embodiment of the present invention, the pharmaceutical formulation is formulated as film coated tablet or bilayer tablet or multilayer tablet or modified release tablet. According to another embodiment of the present invention, the pharmaceutical formulation is formulated in capsule form which is selected from the group comprising hard capsule, soft capsule, and enteric capsule. The capsule comprises at least one type of particle, for example; mini-capsules, mini-tablets, pellets, cores, agglomerates, granules, powders, liposomes, spherical or mixtures thereof.
The pharmaceutical formulation of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
According to another embodiment of the present invention, the formulation is prepared, using wet or dry granulation.
Solvent is used in wet granulation. Suitable solvents are selected from the group comprising dichloromethane, 0.1N HCI, water, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether, propylene carbonate or mixtures thereof. Preferably, solvent is water or ethanol or mixtures thereof.
A wet granulation process for preparing a pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) Mixing linagliptin, metformin and canagliflozin or empagliflozin or dapagliflozin with croscarmellose sodium, microcrystalline cellulose, b) Granulating the mixture with aqueous solution of HPMC, c) Drying the granules and sieving, d) Mixing with mg-stearate, e) Compressing into tablet , f) Performing a film coating with PVA base solution,
A direct compression process for preparing a pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) Mixing linagliptin, metformin DC grade and canagliflozin or empagliflozin or dapagliflozin with croscarmellose sodium, microcrystalline cellulose, b) Adding mg-stearate and sodium stearyl fumarate and mix, c) Compressing into tablets, d) Performing a film coating with PVA base solution. A wet granulation process for preparing a bilayer pharmaceutical formulation comprising linagliptin, metformin and a SGLT-2 inhibitor comprising the following steps: a) As first layer; Granulating metformin with an aqueous solution of Karboksimetilseluloz sodyum (7 HF) and HPMC b) Drying the granules and mixing with mg-stearate, c) As second layer; linagliptin, dapagliflozin, mannitol DC; pregelatinized starch, corn starch, copovidone and crospovidone is mixed. Mixture is lubricated with mg-stearate and talc, d) Optionally, linagliptin could be prepared in film coating solution and coated onto tablets. Example 1: Film coated tablet
Figure imgf000009_0001
Example 2: A tablet
Figure imgf000009_0002
Example 3: A tablet
Figure imgf000010_0001
Example 4: A tablet
Figure imgf000010_0002
Example 5: A tablet
Figure imgf000011_0001

Claims

1) A pharmaceutical formulation comprises;
Linagliptin or salts thereof, metformin or salts thereof, A SGLT-2 inhibitor.
2) The pharmaceutical formulation according to claim 1, wherein SGLT2 inhibitor is selected from the group comprising canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, tofogliflozin.
3) The pharmaceutical formulation according to claim 1, wherein the amount of linagliptin or salts thereof is between 0.1% and 3.0% by weight in the total formulation.
4) The pharmaceutical formulation according to claim 1, wherein the amount of metformin or salts thereof is between 60.0% and 80.0% by weight in the total formulation.
5) The pharmaceutical formulation according to claim 1, wherein the amount of a SGLT2 inhibitor is between 0.1% and 15.0% by weight in the total formulation.
6) The pharmaceutical formulation according to claim 1, wherein further comprising at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants, glidants or mixtures thereof.
7) The pharmaceutical formulation according to claim 6, wherein fillers are selected from the group comprising ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose acetate, compressible sugar, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, lactose, mannitol, lactose monohydrate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, microcrystalline cellulose, polydextrose, polymethacrylates, sodium alginate, sodium chloride, starch, sucrose, sugar spheres, talc, polysorbate 80, xylitol or mixtures thereof.
8) The pharmaceutical formulation according to claim 7, wherein the amount of the filler is between 10.0% and 40.0 by weight in the total formulation.
9) The pharmaceutical formulation according to claim 6, wherein binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, carboxymethylcellulose calcium, cellulose acetate phthalate, starch, corn starch, pregelatinized starch, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropyl methyl cellulose, polyoxyethilene-alkyl ethers or mixtures thereof.
10) The pharmaceutical formulation according to claim 9, wherein the binder is carboxymethylcellulose sodium or polyvinylpyrrolidone or corn starch or HPMC or mixtures thereof.
11) The pharmaceutical formulation according to claim 6, wherein disintegrants are selected from the group comprising crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, sodium alginate, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
12) The pharmaceutical formulation according to claim 11, wherein the amount of disintegrant is between 1.0% and 15.0% by weight in the total formulation.
13) The pharmaceutical formulation according to claim 6, wherein lubricants are selected from the group comprising magnesium stearate, talc, calcium stearate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
14) The pharmaceutical formulation according to claim 6, wherein glidants are selected from the group comprising aluminum silicate, colloidal silicon dioxide, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
15) The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is in the form of tablets, capsules, orally disintegrating tablets, effervescent compositions, hard or soft gelatin capsules, coated bead systems, granules, microspheres.
PCT/TR2024/050639 2023-06-19 2024-06-10 A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor Pending WO2024263130A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2023/007200 TR2023007200A1 (en) 2023-06-19 A PHARMACEUTICAL FORMULATION CONTAINING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
TR2023007200 2023-06-19

Publications (1)

Publication Number Publication Date
WO2024263130A1 true WO2024263130A1 (en) 2024-12-26

Family

ID=93936130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2024/050639 Pending WO2024263130A1 (en) 2023-06-19 2024-06-10 A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor

Country Status (1)

Country Link
WO (1) WO2024263130A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160608A1 (en) * 2020-02-13 2021-08-19 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising linagliptin and metformin
CN115813874A (en) * 2022-12-29 2023-03-21 越洋医药开发(广州)有限公司 Preparation method and preparation of a kind of oral three-party combination hypoglycemic double-release tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160608A1 (en) * 2020-02-13 2021-08-19 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising linagliptin and metformin
CN115813874A (en) * 2022-12-29 2023-03-21 越洋医药开发(广州)有限公司 Preparation method and preparation of a kind of oral three-party combination hypoglycemic double-release tablet

Similar Documents

Publication Publication Date Title
ES2596291T3 (en) Pharmaceutical formulations comprising 1- (beta-d-glucopyranosyl) -2-thienylmethylbenzene derivatives as sglt inhibitors
EP4112047B1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
WO2021176096A1 (en) Pharmaceutical composition comprising sglt2 inhibitor
TWI606848B (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EP3781135A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
KR101512386B1 (en) Complex formulation comprising metformin and mitiglinide and method for preparation thereof
US20150366863A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
WO2019132833A1 (en) The modified release combination comprising linagliptin and metformin
WO2020013777A2 (en) Tablet formulations comprising metformin and sitagliptin
WO2024263130A1 (en) A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor
EP2468267B1 (en) Bilayer Combination Composition of Vildagliptin and Gliclazide
EP4385501A1 (en) A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
EP4008316A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
EP4171533A1 (en) A film coated tablet comprising vildagliptin and metformin hci
EP4385502A1 (en) A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
TR2023007200A1 (en) A PHARMACEUTICAL FORMULATION CONTAINING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
TR2022019413A1 (en) A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, PIOGLITAZONE AND A SGLT-2 INHIBITOR
TR2023007202A1 (en) A PHARMACEUTICAL FORMULATION CONTAINING SAXAGLIPTINE, PIOGLITAZONE AND A SGLT-2 INHIBITOR
TR2023007201A1 (en) A PHARMACEUTICAL FORMULATION CONTAINING VILDAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
EP3781261B1 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor
KR20090107960A (en) Pharmaceutical preparations for the treatment of cardiovascular diseases
WO2023129050A1 (en) A pharmaceutical composition of empagliflozin and linagliptin processed with hot-melt extrusion
EP4456901A1 (en) A pharmaceutical composition of empagliflozin and linagliptin processed with hot-melt extrusion
WO2024263133A1 (en) A monolithic tablet composition comprising linagliptin & metformin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24826376

Country of ref document: EP

Kind code of ref document: A1